search button

Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma

  • Authors:
    • Ignacio García Escobar
    • Ana López
    • Judit Rubio
    • David Pérez‑Callejo
    • Dolores Caballero Barrigón
    • Pilar Tamayo Alonso
    • Elena Almagro Casado
    • Mariano Provencio Pulla

  • View Affiliations

  • Published online on: November 9, 2015     https://doi.org/10.3892/mco.2015.670
  • Pages: 93-99
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study was conducted to investigate the prognostic effect and implications of gallium 67 scintigraphy (gallium scan) at mid‑treatment and at the end of first‑line treatment in patients with early‑ and advanced‑stage Hodgkin's lymphoma (HL). A total of 216 HL patients were included in the study. Gallium scan was performed at mid‑treatment and at the end of first‑line treatment. The overall survival (OS) and event‑free survival (EFS) were calculated using the Kaplan‑Meier method. The log‑rank test was used to identify univariate predictors of EFS and OS. For early‑stage disease, bulky mediastinal involvement (yes vs. no, 98 vs. 79%, respectively; P=0.01), erythrocyte sedimentation rate (good vs. adverse, 98 vs. 88%, respectively; P=0.03), presence of B symptoms (no vs. yes, 94 vs. 78%, respectively; P=0.006), post‑chemotherapy disease status [complete response (CR) vs. unconfirmed CR (uCR) vs. partial response (PR) vs. progressive disease (PGR), 95 vs. 90 vs. 87 vs. 0%, respectively; P<0.01] and gallium scan at mid‑treatment and at the end of treatment (negative vs. positive, 88 vs. 20%, P<0.001; and 85 vs. 10%, P<0.001, respectively) significantly affected the EFS. In addition, age (<50 vs. ≥50 years, 96 vs. 78%, respectively; P=0.01), presence of B symptoms (no vs. yes, 97 vs. 87%, respectively; P=0.03), post‑chemotherapy disease status (CR vs. uCR vs. PR vs. PGR, 95 vs. 90 vs. 90 vs. 0%, respectively; P<0.01) and gallium scan results at mid‑treatment and at the end of treatment (negative vs. positive, 87 vs. 60%, P<0.001; and 95 vs. 0%, P<0.001, respectively) significantly affected the OS. For advanced‑stage disease, Hassenclever index (1-3 vs. 4-6, 80 vs. 57%, respectively; P=0.05) and gallium scan results at mid‑treatment and at the end of treatment (negative vs. positive, 84 vs. 18%, P<0.001; and 84 vs. 0%, P<0.001, respectively) significantly affected the EFS, whereas age at diagnosis (<50 vs. ≥50 years, 92 vs. 78%, respectively; P=0.04), Hassenclever index (1-3 vs. 4-6, 86 vs. 61%, respectively; P=0.04) and gallium scan results at mid‑treatment and at the end of treatment (negative vs. positive, 98 vs. 40%, P<0.001; and 97 vs. 23%, P<0.001, respectively) significantly affected the OS. On the multivariate analysis, gallium scan at the end of first‑line treatment retained statistical significance in terms of EFS and OS. In conclusion, post‑chemotherapy gallium scan is an important prognostic factor in patients with early‑ or advanced‑stage HL and a predictor of adverse outcome.
View References

Related Articles

Journal Cover

January-2016
Volume 4 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Escobar IG, López A, Rubio J, Pérez‑Callejo D, Barrigón DC, Alonso PT, Casado EA and Pulla MP: Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. Mol Clin Oncol 4: 93-99, 2016.
APA
Escobar, I.G., López, A., Rubio, J., Pérez‑Callejo, D., Barrigón, D.C., Alonso, P.T. ... Pulla, M.P. (2016). Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma. Molecular and Clinical Oncology, 4, 93-99. https://doi.org/10.3892/mco.2015.670
MLA
Escobar, I. G., López, A., Rubio, J., Pérez‑Callejo, D., Barrigón, D. C., Alonso, P. T., Casado, E. A., Pulla, M. P."Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma". Molecular and Clinical Oncology 4.1 (2016): 93-99.
Chicago
Escobar, I. G., López, A., Rubio, J., Pérez‑Callejo, D., Barrigón, D. C., Alonso, P. T., Casado, E. A., Pulla, M. P."Clinical pretreatment risk factors and prediction of outcome using gallium 67 scintigraphy in patients with Hodgkin's lymphoma". Molecular and Clinical Oncology 4, no. 1 (2016): 93-99. https://doi.org/10.3892/mco.2015.670